Related Experiment Video
Updated: Jun 22, 2025
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
37.3K
Current and Emerging Therapeutics in Hereditary Angioedema
1Division of Allergy & Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Immunology and Allergy Clinics of North America
|June 27, 2024
Summary
Angioedema involves fluid leakage causing swelling. New therapies target bradykinin-mediated angioedema, significantly improving hereditary angioedema (HAE) management options.
Area of Science:
- Immunology
- Vascular Biology
- Pharmacology
Background:
- Angioedema is defined by interstitial fluid accumulation, causing non-pitting edema.
- Conditions are categorized as mast cell-mediated or bradykinin-mediated.
- Bradykinin-mediated angioedema lacks specific treatments historically, unlike mast cell-mediated types.
Purpose of the Study:
- To review the current understanding of angioedema pathophysiology.
- To highlight recent advancements in therapies for bradykinin-mediated angioedema.
- To discuss the impact of new treatments on hereditary angioedema (HAE) management.
Main Methods:
- Literature review of angioedema mechanisms.
- Analysis of recent clinical studies on bradykinin-mediated angioedema treatments.
- Examination of regulatory approvals for HAE medications.
Main Results:
- Angioedema is classified into mast cell-mediated and bradykinin-mediated types.
- Specific therapies for bradykinin-mediated angioedema have emerged.
- Recent drug approvals have expanded HAE treatment options.
Conclusions:
- Therapeutic options for bradykinin-mediated angioedema have significantly advanced.
- These advancements offer improved management strategies for hereditary angioedema.
- Further research continues to refine angioedema treatment paradigms.
Keywords:
Angioedema management/treatmentC1 inhibitor deficiencyHereditary angioedemaInvestigational therapies for angioedemaMast cell-mediated angioedemaMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:25Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700